Improving Keloids Using Targeted Ultraviolet-B Irradiation
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 2
- 主要终点
- Clinical Appearance As Assessed by the Patient and Observer Scar Assessment (POSAS) Scale
研究概览
简要总结
Treatment of keloids with targeted Ultraviolet-Beta (UVB) radiation will improve the clinical appearance and induration of lesions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants must be 18 years old or over
- •Participants must have a diagnosis of keloid
- •No treatment with topical or intralesional steroids for 1 month prior to study
排除标准
- •Patients who are unable to provide informed consent
- •A history of photosensitivity, lupus erythematosus, porphyria or current use of a known photosensitizing drug
- •Unwillingness to stop with topical or intralesional steroids for 1 month prior to study
- •A history of malignant melanoma
- •A history of radiation therapy to area of interest
- •Subjects who self-report that they are pregnant or nursing
研究组 & 干预措施
Control Group
Keloids that were randomized to a non treatment group, were not exposed to the NB-UVB light.
Treatment Group
Keloids that were randomized to the treatment group, were exposed to Narrowband-UVB (NB-UVB). Targeted UVB will be delivered to the keloid for up to 16 weeks using the Lumera UVB light phototherapy device (Daavlin, Bryan Ohio, USA).The affected skin will be irradiated using a hand-held fiber optic cable with an adjustable aperture.
干预措施: NB-UVB (Device)
结局指标
主要结局
Clinical Appearance As Assessed by the Patient and Observer Scar Assessment (POSAS) Scale
时间窗: 16 weeks
Investigators will evaluate the pre- and post-study clinical photographs of all participants. The grading investigator will grade the degree of improvement using the POSAS scale to measure the clinical appearance of the keloids
次要结局
未报告次要终点